Practical progress and new drugs for changing patterns of leishmaniasis.
about
Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis.Advances in Development of New Treatment for LeishmaniasisCombination therapy with indolylquinoline derivative and sodium antimony gluconate cures established visceral leishmaniasis in hamstersDepletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responsesUnresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical diseaseMapping of a Leishmania major gene/locus that confers pentamidine resistance by deletion and insertion of transposable element.In vitro and in vivo Leishmanicidal activity of 2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone (lapachol).Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.Potential Challenges of Controlling Leishmaniasis in Sri Lanka at a Disease Outbreak.Improvement of in vitro and in vivo antileishmanial activities of 2', 6'-dihydroxy-4'-methoxychalcone by entrapment in poly(D,L-lactide) nanoparticles.Clinical and experimental advances in treatment of visceral leishmaniasis.Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.The therapeutic potential of inhibitors of the trypanothione cycle.Antileishmanial activity of a linalool-rich essential oil from Croton cajucara.Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasisNaturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes.Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune responseL-Asparaginase as a new molecular target against leishmaniasis: insights into the mechanism of action and structure-based inhibitor design.Treatment of Mediterranean visceral leishmaniasis.A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India.An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae.Mucosal leishmaniasis due to Leishmania (Viannia) braziliensis L(V)b in Três Braços, Bahia-Brazil.The Effect of Garlic Extract on Expression of INFγ And Inos Genes in Macrophages Infected with Leishmania majorStage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis.Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones.Low efficacy of azithromycin to treat cutaneous leishmaniasis in Manaus, AM, Brazil.Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate.Antiparasitic effects of the intra-Golgi transport inhibitor megalomicin.Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial.Antileishmanial activities of several classes of aromatic dications.Synthesis and leishmanicidal activity of 2,3,4-substituted-5-imidazolones.In vitro leishmanicidal activity of naturally occurring chalcones.Activity of imidazole compounds on Leishmania (L.) infantum chagasi: reactive oxygen species induced by econazole.Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial.Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.In vitro activity of Triclisia patens and some bisbenzylisoquinoline alkaloids against Leishmania donovani and Trypanosoma brucei brucei.Azithromycin in the treatment of mucosal leishmaniasis.5-Nitroisatin-derived thiosemicarbazones: potential antileishmanial agents.
P2860
Q24535789-BABD1906-C980-4484-B7E4-7B30A398F20DQ28082097-8F392724-6629-4EFA-9100-0A5197118C7FQ28366821-ADE8374B-A846-40BA-BE25-5E2B14754495Q28369065-57C02E01-E024-444C-BA5F-A89CD4DECB9CQ28468760-A1248FB8-F643-4E57-9235-D4383B9F33DAQ30426102-36270C4D-EE2D-4B3A-B98C-D4F0E01CB288Q31061018-8A3F1ACF-5902-48FA-9A2A-651929B5DE6BQ31949503-4E86AFF6-373E-4E5A-8F8E-BC60CE8BBBA8Q33779256-4B3112CC-2904-45AA-A0E7-F1142EC66C0BQ33786761-09BAE47F-BF92-43FA-818F-D12DD5453B04Q33977249-08A7052B-ECF4-4DC1-8C24-B442AD19804AQ33982648-41DA65E6-05A1-4735-B8CD-50A85CFB1844Q34128082-EA8D28A1-2851-4B81-BEDF-357BE4183DFDQ34519134-7773B931-D60F-4E5B-83DB-29129491EDDAQ35013732-AFDB4346-9286-4CEB-87CC-145871D9936BQ35122890-046D9CAD-26E1-4E1F-9B1C-B4D781548941Q35130083-66BBDA82-8DED-46FE-8D15-EC6E6D995CC3Q35448239-6668913D-B26B-4C99-BBC1-8D8E4931021CQ35609857-82AC2880-DB88-478B-8313-92DC9FE2627FQ36794770-727541E2-B59C-4253-B50F-9F040B07899BQ37230269-91139727-BF79-4C8B-A4DB-16F3F3D9A9C4Q37713114-F3BE475F-EDFD-4AA6-8417-B4E7F801CFF6Q39217364-A66F685E-2CED-427F-AA50-4A4C5EE6A67FQ39394132-2B1E26A1-EF2B-4481-B0A9-9A281120BEA6Q39469739-DB312E69-A246-4A14-A6F1-7D9A8D812CF0Q39470145-8AF19A85-E504-4807-A200-90C0240B7D62Q39477746-54249168-9DC3-4441-98E0-D61543C31F62Q39515708-0A206892-40BC-4181-A6A7-DF4B44C759C7Q39557983-0D2168AE-A14F-496B-B358-6D4E8C6CABAFQ39559177-69D34285-4A0F-4CCC-99AC-78E412EFBA1BQ39566759-F89A6FBF-80C2-459C-9AA1-CFEB0049CD0EQ39653055-019F4452-AA4C-42A0-BAEE-A3D29EEB65DAQ43210273-2F228A85-C4A2-4313-996B-F95F7F51CD14Q43553643-A770B91E-B6F9-426B-9563-3A6C9E14AC18Q43563878-9BE5F626-BA81-4569-A2BA-07970B22B730Q43975398-B7A13412-04C2-4D46-9D81-F0316B5564C5Q44066578-3A04F6A9-5E88-42B7-924C-880B302C757AQ44119642-280815D2-5D88-4578-BE02-A7BDD05CC705Q45001912-A60659C1-AB2B-4A00-A9C5-0DB6C562890BQ45863178-ED798DBA-A7FB-4BEA-9756-262268119CE5
P2860
Practical progress and new drugs for changing patterns of leishmaniasis.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Practical progress and new drugs for changing patterns of leishmaniasis.
@en
Practical progress and new drugs for changing patterns of leishmaniasis.
@nl
type
label
Practical progress and new drugs for changing patterns of leishmaniasis.
@en
Practical progress and new drugs for changing patterns of leishmaniasis.
@nl
prefLabel
Practical progress and new drugs for changing patterns of leishmaniasis.
@en
Practical progress and new drugs for changing patterns of leishmaniasis.
@nl
P1476
Practical progress and new drugs for changing patterns of leishmaniasis.
@en
P2093
Bryceson AD
Olliaro PL
P304
P356
10.1016/0169-4758(93)90231-4
P577
1993-09-01T00:00:00Z